JP2018531013A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531013A5 JP2018531013A5 JP2018518522A JP2018518522A JP2018531013A5 JP 2018531013 A5 JP2018531013 A5 JP 2018531013A5 JP 2018518522 A JP2018518522 A JP 2018518522A JP 2018518522 A JP2018518522 A JP 2018518522A JP 2018531013 A5 JP2018531013 A5 JP 2018531013A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- engineered nucleic
- acid construct
- acid encoding
- engineered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000039446 nucleic acids Human genes 0.000 claims 29
- 108020004707 nucleic acids Proteins 0.000 claims 29
- 150000007523 nucleic acids Chemical class 0.000 claims 29
- 101710163270 Nuclease Proteins 0.000 claims 9
- 230000004568 DNA-binding Effects 0.000 claims 7
- 108091033409 CRISPR Proteins 0.000 claims 4
- 102000015694 estrogen receptors Human genes 0.000 claims 4
- 108010038795 estrogen receptors Proteins 0.000 claims 4
- 238000011144 upstream manufacturing Methods 0.000 claims 4
- 108090000790 Enzymes Proteins 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 3
- 108020005004 Guide RNA Proteins 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 238000011830 transgenic mouse model Methods 0.000 claims 3
- 241000699666 Mus <mouse, genus> Species 0.000 claims 2
- 241000699660 Mus musculus Species 0.000 claims 2
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 102000034356 gene-regulatory proteins Human genes 0.000 claims 2
- 108091006104 gene-regulatory proteins Proteins 0.000 claims 2
- 239000012212 insulator Substances 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 claims 1
- 102100035620 Protein phosphatase 1 regulatory subunit 12C Human genes 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562242884P | 2015-10-16 | 2015-10-16 | |
| US62/242,884 | 2015-10-16 | ||
| PCT/IB2016/001902 WO2017064566A2 (en) | 2015-10-16 | 2016-10-14 | Inducible modification of a cell genome |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2018531013A JP2018531013A (ja) | 2018-10-25 |
| JP2018531013A6 JP2018531013A6 (ja) | 2018-12-13 |
| JP2018531013A5 true JP2018531013A5 (enExample) | 2019-11-28 |
| JP6936952B2 JP6936952B2 (ja) | 2021-09-22 |
Family
ID=58054378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018518522A Active JP6936952B2 (ja) | 2015-10-16 | 2016-10-14 | 細胞ゲノムの誘導性改変 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10947559B2 (enExample) |
| EP (1) | EP3362561A2 (enExample) |
| JP (1) | JP6936952B2 (enExample) |
| CN (1) | CN108431225A (enExample) |
| AU (1) | AU2016337408B2 (enExample) |
| CA (1) | CA3001518A1 (enExample) |
| WO (1) | WO2017064566A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| AU2016337408B2 (en) * | 2015-10-16 | 2022-11-03 | Astrazeneca Ab | Inducible modification of a cell genome |
| WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| SG11201803151PA (en) | 2015-11-05 | 2018-05-30 | Agency Science Tech & Res | Chemical-inducible genome engineering technology |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| KR20240007715A (ko) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| KR20190123328A (ko) | 2017-03-09 | 2019-10-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 암 백신 |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
| IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| US12054733B2 (en) | 2017-06-16 | 2024-08-06 | Lonza Ltd | Universal self-regulating mammalian cell line platform for the production of biologics |
| KR101928659B1 (ko) * | 2017-06-19 | 2018-12-13 | 서울대학교병원 | Dna 변형 유도 단백질 복합체 및 이를 암호화하는 유전자를 포함하는 재조합 벡터 |
| EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| WO2020028533A1 (en) * | 2018-08-01 | 2020-02-06 | Yale University | Compositions and methods for identification of membrane targets for enhancement of t cell activity against cancer |
| JP2022513347A (ja) * | 2018-10-11 | 2022-02-07 | アイドゲノーシッシェ テヒニッシェ ホッホシューレ チューリッヒ | 高度にコンパクトな多入力論理ゲートをコードする核酸ベクターを使用して疾患を処置する方法 |
| US11851663B2 (en) * | 2018-10-14 | 2023-12-26 | Snipr Biome Aps | Single-vector type I vectors |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| WO2020191241A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| WO2021111280A1 (en) * | 2019-12-04 | 2021-06-10 | Crispr Therapeutics Ag | Regulatable expression systems |
| CA3177481A1 (en) | 2020-05-08 | 2021-11-11 | David R. Liu | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| CN111705080A (zh) * | 2020-05-14 | 2020-09-25 | 广州市第八人民医院 | Hbv非人动物模型的构建方法及其应用 |
| CN116262927B (zh) * | 2021-12-13 | 2024-04-26 | 中国科学院微生物研究所 | 基于CRISPR/Cas系统调控基因表达的方法及其应用 |
| WO2024231559A1 (en) | 2023-05-11 | 2024-11-14 | Astrazeneca Ab | Methods of treatment of chronic kidney disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| JP2008503541A (ja) | 2004-06-21 | 2008-02-07 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | グリコシル化分裂型因子ｖｉｉ変異体 |
| JP4811765B2 (ja) * | 2004-06-22 | 2011-11-09 | 学校法人東海大学 | 外来遺伝子の誘導発現の制御が可能な発現ベクター |
| CN116622704A (zh) | 2012-07-25 | 2023-08-22 | 布罗德研究所有限公司 | 可诱导的dna结合蛋白和基因组干扰工具及其应用 |
| KR102955556B1 (ko) * | 2012-12-12 | 2026-04-22 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물 |
| AU2016337408B2 (en) * | 2015-10-16 | 2022-11-03 | Astrazeneca Ab | Inducible modification of a cell genome |
-
2016
- 2016-10-14 AU AU2016337408A patent/AU2016337408B2/en active Active
- 2016-10-14 CA CA3001518A patent/CA3001518A1/en active Pending
- 2016-10-14 EP EP16837979.0A patent/EP3362561A2/en active Pending
- 2016-10-14 WO PCT/IB2016/001902 patent/WO2017064566A2/en not_active Ceased
- 2016-10-14 CN CN201680074288.4A patent/CN108431225A/zh active Pending
- 2016-10-14 US US15/768,482 patent/US10947559B2/en active Active
- 2016-10-14 JP JP2018518522A patent/JP6936952B2/ja active Active
-
2021
- 2021-02-03 US US17/166,823 patent/US12509702B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2025263805A1 (en) | Novel crispr enzymes and systems | |
| Lone et al. | CRISPR/Cas9 system: a bacterial tailor for genomic engineering | |
| Senís et al. | CRISPR/Cas9‐mediated genome engineering: an adeno‐associated viral (AAV) vector toolbox | |
| CN108546716A (zh) | 一种基因组编辑方法 | |
| JP2021532815A (ja) | 新規Ｃａｓ１２ｂ酵素およびシステム | |
| JP2019115348A5 (enExample) | ||
| EP3222728A1 (en) | Method for regulating gene expression using cas9 protein expressed from two vectors | |
| MX2021004455A (es) | Composiciones y métodos para administrar transgenes. | |
| IL295858B2 (en) | gRNA molecules including TRACR and crRNA, compositions containing them and their use | |
| CN105886498A (zh) | CRISPR-Cas9特异性敲除人PCSK9基因的方法以及用于特异性靶向PCSK9基因的sgRNA | |
| CN105646719A (zh) | 一种高效定点转基因的工具及其应用 | |
| JPWO2017090724A1 (ja) | Ｄｎａメチル化編集用キットおよびｄｎａメチル化編集方法 | |
| JP2016500262A5 (enExample) | ||
| HRP20201443T1 (hr) | Postupci i pripravci za liječenje genetskog stanja | |
| CN108690845A (zh) | 基因组编辑系统和方法 | |
| Nishizawa‐Yokoi et al. | A piggyBac‐mediated transgenesis system for the temporary expression of CRISPR/Cas9 in rice | |
| JP2009532053A5 (enExample) | ||
| Bayoumi et al. | Potential use of CRISPR/cas13 machinery in understanding virus–host interaction | |
| JP2022526646A5 (enExample) | ||
| MX356630B (es) | Uso del promotor rd29 o fragmentos del mismo para expresión de transgenes inducible por estrés en algodón. | |
| WO2013030176A3 (en) | Live attenuated influenza virus | |
| Gupta et al. | Modification of Cas9, gRNA and PAM: key to further regulate genome editing and its applications | |
| Pflueger et al. | Harnessing targeted DNA methylation and demethylation using dCas9 | |
| WO2025096916A1 (en) | Multi-site editing in living cells | |
| JP2024501892A (ja) | 新規の核酸誘導型ヌクレアーゼ |